雲頂新耀-B(01952.HK)終止與Providence疫苗授權許可 另制定新條款合作
雲頂新耀-B(01952.HK)公布,公司與Providence訂立終止協議,雙方全面終止合作及授權許可協議、COVID-19疫苗授權許可協議及股份發行協議,自上周五(16日)起生效。除初始預付款1億美元及於第三批里程碑交割時向Providence發行349.24萬股股份外,公司並無根據該等協議向Providence支付任何款項或發行任何股份。
此外,雙方制定新條款,可使用任何合作產品及雲頂新耀可使用任何其他產品(包括COVID-19疫苗)。具體而言,雙方同意Providence授予公司全球性、永久及不可撤銷、免特許權費用、非獨家的授權,並有權部分再授權合作產品及其他產品;雙方各自擁有其於生效日期後開發的任何知識產權;及雙方共同擁有與根據該等協議開發的狂犬病疫苗項目等相關的若干知識產權(包括如該等公告所述與Providence合作開發用於狂犬病暴露後預金金防性信使核糖核酸(mRNA)狂犬病候選疫苗)。
根據終止協議,公司須向Providence支付一次性付款400萬美元,及倘公司決定開發合作產品,則需支付潛在監管里程碑付款,最多為1,750萬美元。此外,公司須向Providence支付於Providence權益地區銷售合作產品的特許權費用,及Providence須向公司支付於雲頂新耀權益地區銷售合作產品的特許權費用,兩者按照適用特許權費用支付期間內合作產品總銷售淨額的低個位數百分比費率計算。
公司認為,終止協議並不會對其業務經營及財務狀況造成任何重大不利影響;及將為公司提供更大靈活性,使公司能夠在適當情況下根據其企業策略及目標,使用公司從Providence獲得授權許可的mRNA平台開發產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.